Summary:
Our M23-072 Migraine study is looking at 2 newly FDA approved medications called Atogepant and Ubrogepant. It is a Phase 4 Open-Label treatment study so you will be receiving the medications during this study. The purpose is to evaluate the Safety, Tolerability, and Efficacy of the Concomitant Use of Ubrogepant for the Acute Treatment of Migraine in Subjects taking Atogepant for the Preventative Treatment of Episodic Migraines.
Who is Qualified?:
- Participants who are generally healthy and between 18-80 years old. (We also have a study for those 13-17)
- Participants who have between 4-14 Migraine and Headache days combined per month.
- No medication history necessary to qualify.
- Insurance not required to qualify.
- Participants willing to add a medication to their current treatment. (It is possible to take psychiatric medication or some pain medications during the study.)
Qualified Participants Can Receive:
- $77 in Compensation after each completed appointment.
- 58.5 cents per mile for gas reimbursement up to $53 per visit.
- FDA approved Migraine medications at no cost.
- Free labs and blood work during the initial visit and through the study.
How long are these studies?
- This study in 29 weeks (7.2 months) with 9 scheduled visits at our office in Oceanside.
- Studies are voluntary in the sense that you can stop at any moment; You are paid after each completed appointment between $77 plus transportation reimbursement up to $53 per visit.
- Each visit will be about an hour besides the initial screening visit which is normally 3-4 hours.